<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d139" origId="Ibandronate"><sentence id="DrugDDI.d139.s0" origId="s0" text="Calcium Supplements/Antacids"><entity charOffset="0-7" id="DrugDDI.d139.s0.e0" origId="s0.p0" text="Calcium" type="drug"/><entity charOffset="20-28" id="DrugDDI.d139.s0.e1" origId="s0.p2" text="Antacids" type="drug"/><pair e1="DrugDDI.d139.s0.e0" e2="DrugDDI.d139.s0.e1" id="DrugDDI.d139.s0.p0" interaction="false"/></sentence><sentence id="DrugDDI.d139.s1" origId="s1" text="Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate."><entity charOffset="20-27" id="DrugDDI.d139.s1.e0" origId="s1.p5" text="calcium" type="drug"/><entity charOffset="50-57" id="DrugDDI.d139.s1.e1" origId="s1.p7" text="cations" type="drug"/><entity charOffset="77-86" id="DrugDDI.d139.s1.e2" origId="s1.p10" text="magnesium" type="drug"/><entity charOffset="88-92" id="DrugDDI.d139.s1.e3" origId="s1.p11" text="iron" type="drug"/><entity charOffset="137-148" id="DrugDDI.d139.s1.e4" origId="s1.p17" text="Ibandronate" type="drug"/><pair e1="DrugDDI.d139.s1.e0" e2="DrugDDI.d139.s1.e1" id="DrugDDI.d139.s1.p0" interaction="false"/><pair e1="DrugDDI.d139.s1.e0" e2="DrugDDI.d139.s1.e2" id="DrugDDI.d139.s1.p1" interaction="false"/><pair e1="DrugDDI.d139.s1.e0" e2="DrugDDI.d139.s1.e3" id="DrugDDI.d139.s1.p2" interaction="false"/><pair e1="DrugDDI.d139.s1.e0" e2="DrugDDI.d139.s1.e4" id="DrugDDI.d139.s1.p3" interaction="false"/><pair e1="DrugDDI.d139.s1.e1" e2="DrugDDI.d139.s1.e2" id="DrugDDI.d139.s1.p4" interaction="false"/><pair e1="DrugDDI.d139.s1.e1" e2="DrugDDI.d139.s1.e3" id="DrugDDI.d139.s1.p5" interaction="false"/><pair e1="DrugDDI.d139.s1.e1" e2="DrugDDI.d139.s1.e4" id="DrugDDI.d139.s1.p6" interaction="false"/><pair e1="DrugDDI.d139.s1.e2" e2="DrugDDI.d139.s1.e3" id="DrugDDI.d139.s1.p7" interaction="false"/><pair e1="DrugDDI.d139.s1.e2" e2="DrugDDI.d139.s1.e4" id="DrugDDI.d139.s1.p8" interaction="true"/><pair e1="DrugDDI.d139.s1.e3" e2="DrugDDI.d139.s1.e4" id="DrugDDI.d139.s1.p9" interaction="false"/></sentence><sentence id="DrugDDI.d139.s2" origId="s2" text="Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins)."><entity charOffset="0-11" id="DrugDDI.d139.s2.e0" origId="s2.p18" text="Ibandronate" type="drug"/><entity charOffset="99-106" id="DrugDDI.d139.s2.e1" origId="s2.p25" text="cations" type="drug"/><entity charOffset="118-126" id="DrugDDI.d139.s2.e2" origId="s2.p28" text="antacids" type="drug"/><entity charOffset="143-151" id="DrugDDI.d139.s2.e3" origId="s2.p31" text="vitamins" type="drug"/><pair e1="DrugDDI.d139.s2.e0" e2="DrugDDI.d139.s2.e1" id="DrugDDI.d139.s2.p0" interaction="false"/><pair e1="DrugDDI.d139.s2.e0" e2="DrugDDI.d139.s2.e2" id="DrugDDI.d139.s2.p1" interaction="true"/><pair e1="DrugDDI.d139.s2.e0" e2="DrugDDI.d139.s2.e3" id="DrugDDI.d139.s2.p2" interaction="false"/><pair e1="DrugDDI.d139.s2.e1" e2="DrugDDI.d139.s2.e2" id="DrugDDI.d139.s2.p3" interaction="false"/><pair e1="DrugDDI.d139.s2.e1" e2="DrugDDI.d139.s2.e3" id="DrugDDI.d139.s2.p4" interaction="false"/><pair e1="DrugDDI.d139.s2.e2" e2="DrugDDI.d139.s2.e3" id="DrugDDI.d139.s2.p5" interaction="false"/></sentence><sentence id="DrugDDI.d139.s3" origId="s3" text="H2 Blockers and Proton Pump Inhibitors (PPIs)"><entity charOffset="0-11" id="DrugDDI.d139.s3.e0" origId="s3.p33" text="H2 Blockers" type="drug"/><entity charOffset="16-38" id="DrugDDI.d139.s3.e1" origId="s3.p35" text="Proton Pump Inhibitors" type="drug"/><pair e1="DrugDDI.d139.s3.e0" e2="DrugDDI.d139.s3.e1" id="DrugDDI.d139.s3.p0" interaction="false"/></sentence><sentence id="DrugDDI.d139.s4" origId="s4" text="Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2 blockers and PPIs)."><entity charOffset="38-49" id="DrugDDI.d139.s4.e0" origId="s4.p41" text="Ibandronate" type="drug"/><entity charOffset="106-124" id="DrugDDI.d139.s4.e1" origId="s4.p44" text="anti-peptic agents" type="drug"/><entity charOffset="136-147" id="DrugDDI.d139.s4.e2" origId="s4.p46" text="H2 blockers" type="drug"/><pair e1="DrugDDI.d139.s4.e0" e2="DrugDDI.d139.s4.e1" id="DrugDDI.d139.s4.p0" interaction="false"/><pair e1="DrugDDI.d139.s4.e0" e2="DrugDDI.d139.s4.e2" id="DrugDDI.d139.s4.p1" interaction="false"/><pair e1="DrugDDI.d139.s4.e1" e2="DrugDDI.d139.s4.e2" id="DrugDDI.d139.s4.p2" interaction="false"/></sentence><sentence id="DrugDDI.d139.s5" origId="s5" text="Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate was similar to that in placebo-treated patients."><entity charOffset="111-122" id="DrugDDI.d139.s5.e0" origId="s5.p55" text="Ibandronate" type="drug"/></sentence><sentence id="DrugDDI.d139.s6" origId="s6" text="Similarly, of over 1600 patients enrolled in a study comparing once-monthly with daily dosing regimens of ibandronate, 14% of patients used anti-peptic agents."><entity charOffset="106-117" id="DrugDDI.d139.s6.e0" origId="s6.p67" text="ibandronate" type="drug"/><entity charOffset="140-158" id="DrugDDI.d139.s6.e1" origId="s6.p71" text="anti-peptic agents" type="drug"/><pair e1="DrugDDI.d139.s6.e0" e2="DrugDDI.d139.s6.e1" id="DrugDDI.d139.s6.p0" interaction="false"/></sentence><sentence id="DrugDDI.d139.s7" origId="s7" text="Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate 150 mg once monthly was similar to that in patients treated with Ibandronate 2.5 mg once daily."><entity charOffset="111-129" id="DrugDDI.d139.s7.e0" origId="s7.p77" text="Ibandronate 150 mg" type="drug"/><entity charOffset="188-206" id="DrugDDI.d139.s7.e1" origId="s7.p85" text="Ibandronate 2.5 mg" type="drug"/><pair e1="DrugDDI.d139.s7.e0" e2="DrugDDI.d139.s7.e1" id="DrugDDI.d139.s7.p0" interaction="false"/></sentence><sentence id="DrugDDI.d139.s8" origId="s8" text="Aspirin/Nonsteroidal Antiinflammatory Drugs (NSAIDs)"><entity charOffset="0-7" id="DrugDDI.d139.s8.e0" origId="s8.p87" text="Aspirin" type="drug"/><entity charOffset="8-42" id="DrugDDI.d139.s8.e1" origId="s8.p88" text="Nonsteroidal Antiinflammatory Drug" type="drug"/><entity charOffset="45-51" id="DrugDDI.d139.s8.e2" origId="s8.p90" text="NSAIDs" type="drug"/><pair e1="DrugDDI.d139.s8.e0" e2="DrugDDI.d139.s8.e1" id="DrugDDI.d139.s8.p0" interaction="false"/><pair e1="DrugDDI.d139.s8.e0" e2="DrugDDI.d139.s8.e2" id="DrugDDI.d139.s8.p1" interaction="false"/><pair e1="DrugDDI.d139.s8.e1" e2="DrugDDI.d139.s8.e2" id="DrugDDI.d139.s8.p2" interaction="false"/></sentence><sentence id="DrugDDI.d139.s9" origId="s9" text="In the large, placebo-controlled osteoporosis Treatment Study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 62% of the 2946 patients."><entity charOffset="63-70" id="DrugDDI.d139.s9.e0" origId="s9.p93" text="aspirin" type="drug"/><entity charOffset="75-111" id="DrugDDI.d139.s9.e1" origId="s9.p95" text="nonsteroidal anti-inflammatory drugs" type="drug"/><pair e1="DrugDDI.d139.s9.e0" e2="DrugDDI.d139.s9.e1" id="DrugDDI.d139.s9.p0" interaction="false"/></sentence><sentence id="DrugDDI.d139.s10" origId="s10" text="Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate 2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%)."><entity charOffset="6-13" id="DrugDDI.d139.s10.e0" origId="s10.p100" text="aspirin" type="drug"/><entity charOffset="17-22" id="DrugDDI.d139.s10.e1" origId="s10.p102" text="NSAID" type="drug"/><entity charOffset="110-128" id="DrugDDI.d139.s10.e2" origId="s10.p107" text="ibandronate 2.5 mg" type="drug"/><pair e1="DrugDDI.d139.s10.e0" e2="DrugDDI.d139.s10.e1" id="DrugDDI.d139.s10.p0" interaction="false"/><pair e1="DrugDDI.d139.s10.e0" e2="DrugDDI.d139.s10.e2" id="DrugDDI.d139.s10.p1" interaction="false"/><pair e1="DrugDDI.d139.s10.e1" e2="DrugDDI.d139.s10.e2" id="DrugDDI.d139.s10.p2" interaction="false"/></sentence><sentence id="DrugDDI.d139.s11" origId="s11" text="Similarly, in the 1-year monthly comparison study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 39% of the 1602 patients."><entity charOffset="51-58" id="DrugDDI.d139.s11.e0" origId="s11.p121" text="aspirin" type="drug"/><entity charOffset="63-99" id="DrugDDI.d139.s11.e1" origId="s11.p123" text="nonsteroidal anti-inflammatory drugs" type="drug"/><pair e1="DrugDDI.d139.s11.e0" e2="DrugDDI.d139.s11.e1" id="DrugDDI.d139.s11.p0" interaction="false"/></sentence><sentence id="DrugDDI.d139.s12" origId="s12" text="The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate 2.5 mg daily (21.7%) and 150 mg once monthly (22.0%)."><entity charOffset="80-87" id="DrugDDI.d139.s12.e0" origId="s12.p132" text="aspirin" type="drug"/><entity charOffset="91-97" id="DrugDDI.d139.s12.e1" origId="s12.p134" text="NSAIDs" type="drug"/><entity charOffset="129-147" id="DrugDDI.d139.s12.e2" origId="s12.p139" text="ibandronate 2.5 mg" type="drug"/><pair e1="DrugDDI.d139.s12.e0" e2="DrugDDI.d139.s12.e1" id="DrugDDI.d139.s12.p0" interaction="false"/><pair e1="DrugDDI.d139.s12.e0" e2="DrugDDI.d139.s12.e2" id="DrugDDI.d139.s12.p1" interaction="false"/><pair e1="DrugDDI.d139.s12.e1" e2="DrugDDI.d139.s12.e2" id="DrugDDI.d139.s12.p2" interaction="false"/></sentence><sentence id="DrugDDI.d139.s13" origId="s13" text="However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate."><entity charOffset="15-22" id="DrugDDI.d139.s13.e0" origId="s13.p152" text="aspirin" type="drug"/><entity charOffset="24-30" id="DrugDDI.d139.s13.e1" origId="s13.p153" text="NSAIDs" type="drug"/><entity charOffset="36-51" id="DrugDDI.d139.s13.e2" origId="s13.p155" text="bisphosphonates" type="drug"/><entity charOffset="159-166" id="DrugDDI.d139.s13.e3" origId="s13.p165" text="aspirin" type="drug"/><entity charOffset="170-176" id="DrugDDI.d139.s13.e4" origId="s13.p167" text="NSAIDs" type="drug"/><entity charOffset="182-193" id="DrugDDI.d139.s13.e5" origId="s13.p168" text="Ibandronate" type="drug"/><pair e1="DrugDDI.d139.s13.e0" e2="DrugDDI.d139.s13.e1" id="DrugDDI.d139.s13.p0" interaction="false"/><pair e1="DrugDDI.d139.s13.e0" e2="DrugDDI.d139.s13.e2" id="DrugDDI.d139.s13.p1" interaction="false"/><pair e1="DrugDDI.d139.s13.e0" e2="DrugDDI.d139.s13.e3" id="DrugDDI.d139.s13.p2" interaction="false"/><pair e1="DrugDDI.d139.s13.e0" e2="DrugDDI.d139.s13.e4" id="DrugDDI.d139.s13.p3" interaction="false"/><pair e1="DrugDDI.d139.s13.e0" e2="DrugDDI.d139.s13.e5" id="DrugDDI.d139.s13.p4" interaction="false"/><pair e1="DrugDDI.d139.s13.e1" e2="DrugDDI.d139.s13.e2" id="DrugDDI.d139.s13.p5" interaction="false"/><pair e1="DrugDDI.d139.s13.e1" e2="DrugDDI.d139.s13.e3" id="DrugDDI.d139.s13.p6" interaction="false"/><pair e1="DrugDDI.d139.s13.e1" e2="DrugDDI.d139.s13.e4" id="DrugDDI.d139.s13.p7" interaction="false"/><pair e1="DrugDDI.d139.s13.e1" e2="DrugDDI.d139.s13.e5" id="DrugDDI.d139.s13.p8" interaction="false"/><pair e1="DrugDDI.d139.s13.e2" e2="DrugDDI.d139.s13.e3" id="DrugDDI.d139.s13.p9" interaction="false"/><pair e1="DrugDDI.d139.s13.e2" e2="DrugDDI.d139.s13.e4" id="DrugDDI.d139.s13.p10" interaction="false"/><pair e1="DrugDDI.d139.s13.e2" e2="DrugDDI.d139.s13.e5" id="DrugDDI.d139.s13.p11" interaction="false"/><pair e1="DrugDDI.d139.s13.e3" e2="DrugDDI.d139.s13.e4" id="DrugDDI.d139.s13.p12" interaction="false"/><pair e1="DrugDDI.d139.s13.e3" e2="DrugDDI.d139.s13.e5" id="DrugDDI.d139.s13.p13" interaction="true"/><pair e1="DrugDDI.d139.s13.e4" e2="DrugDDI.d139.s13.e5" id="DrugDDI.d139.s13.p14" interaction="false"/></sentence><sentence id="DrugDDI.d139.s14" origId="s14" text="Drug/Laboratory Test Interactions"><entity charOffset="0-4" id="DrugDDI.d139.s14.e0" origId="s14.p169" text="Drug" type="drug"/></sentence><sentence id="DrugDDI.d139.s15" origId="s15" text="Bisphosphonates are known to interfere with the use of bone-imaging agents."><entity charOffset="0-15" id="DrugDDI.d139.s15.e0" origId="s15.p171" text="Bisphosphonates" type="drug"/></sentence><sentence id="DrugDDI.d139.s16" origId="s16" text="Specific studies with ibandronate have not been performed."><entity charOffset="22-33" id="DrugDDI.d139.s16.e0" origId="s16.p179" text="ibandronate" type="drug"/><negationtags>&lt;xcope&gt;Specific studies with ibandronate have &lt;cue&gt;not&lt;/cue&gt; been performed&lt;/xcope&gt;.</negationtags></sentence></document>